Brief reportParent Evaluation of Spasticity Treatment in Cerebral Palsy Using Botulinum Toxin Type A
Section snippets
Participants and Setting
After receiving institutional review board approval for the study, we formed a convenience sample. Sixty-five consecutive care providers (eg, parents, foster parents) who brought their children for BTX-A injections to an outpatient, hospital-based clinic of a large regional children’s specialty health care center in Minneapolis were asked to complete a treatment evaluation survey. On checking in, care providers were given the survey and asked to complete it before the clinic appointment began.
Results
Sixty surveys were returned (92%) and 59 (98%) were retained (1 survey was not completed correctly). Forty-three (74%) were completed by female respondents (79% biologic mothers) from 2 parent households (80%). The mean age of all respondents ± standard deviation (SD), was 41.5±9.2 years (range, 22.9−69.5y). The patients ranged in age from 10.8 months to 39 years (mean, 10.9y) and 38 (64%) were boys. Twenty-two percent (n=13) of the respondents characterized their child’s disability as mild,
Discussion
Our main purpose in this preliminary survey was to evaluate parental report of the acceptability of BTX-A treatment for their child’s spasticity, and to evaluate whether treatment acceptability ratings varied in relation to parent or child demographics. Overall, there were moderate to high levels of satisfaction reported and no significant differences were found for raters in regard to age of parent rater or child, sex of parent rater or child, marital status of parent rater, severity of
Conclusions
The value of evaluating treatment procedures and outcomes from different perspectives is underscored by increasing emphasis on measures that complement but go beyond traditional clinical efficacy endpoints.5 One reason for this is a need to understand the factors that influence whether patients and their families adhere to treatments. A treatment may be efficacious but have little impact if it is not followed or implemented. In this study, the TEI provided preliminary evidence that parents
References (10)
- et al.
Botulinum toxin type A neuromuscular blockage in the treatment of lower extremity spasticity in cerebral palsy: a randomized, double-blind, placebo-controlled trialBOTOX Study Group
J Pediatr Orthop
(2000) - et al.
Management of spasticity associated pain with botulinum toxin A
J Pain Sympt Manage
(2000) - et al.
Botulinum toxin treatment of spastic equinus in cerebral palsy: a randomized trial comparing two injection sites
Am J Phys Med Rehabil
(2005) - et al.
The Pediatric Quality of Life Inventory: an evaluation of its reliability and validity for children with traumatic brain injury
Arch Phys Med Rehabil
(2005) - et al.
Use of botulinum toxin type A in pediatric patients with cerebral palsy: a three-center retrospective chart review
J Child Neurol
(2001)
Cited by (11)
Sedation-analgesia protocol for the injection of botulinum toxin A in cerebral palsy
2019, Anales de PediatriaVisual Analogue Scale to score the effects of Botulinum Toxin A treatment in children with cerebral palsy in daily clinical practice
2008, European Journal of Paediatric NeurologyCitation Excerpt :Several studies have shown the benefits of intramuscular Botulinum Toxin Type A (BTX-A) injections for the management of spasticity in children with CP.3–5 Studies indicate that parents of children with CP consider BTX-A treatment to be an acceptable form of treatment.6 BTX-A inhibits cholinergic transmission at neuromuscular synapses and relaxes muscles.
Parental Evaluation and Botulinum Toxin Type A
2007, Archives of Physical Medicine and RehabilitationCan Biomarkers Differentiate Pain and No Pain Subgroups of Nonverbal Children with Cerebral Palsy? A Preliminary Investigation Based on Noninvasive Saliva Sampling
2015, Pain Medicine (United States)Citation Excerpt :This may be because biochemical factors, which are undetectable by imaging, are contributing to a chronic pain state. Because of problems related to self-report and cognitive, motor, and sensory impairments, adequate pain management often eludes individuals with neurodevelopmental disabilities [7]. Therapeutic decisions are frequently based on trial and error, creating a situation frustrating to physicians and nurses as well as individual patients and their families.
Supported in part by a McKnight Land-Grant Professorship.
No commercial party having a direct financial interest in the results of the research supporting this article has or will confer a benefit upon the author(s) or upon any organization with which the author(s) is/are associated.